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Abstract
Background Weight loss has been found to improve or re-
solve cardiovascular comorbidities. There is a significant need
for reversible device approaches to weight loss.
Methods Non-constrictive cuff (NCC) is made of implantable
silicone rubber with an internal diameter greater than the
duodenum. Ten or 11 NCC were individually mounted along
the duodenum from the pyloric sphincter toward the distal
duodenum to cover ~22 mm in the length. Twelve Wistar rats
were implanted with NCC, and six served as sham, and both
groups were observed over 4 months. Six rats with implant
had their NCC removed and were observed for additional
4 weeks.
Results The food intake decreased from 40.1 to 28.1 g/day
after 4 months of NCC implant. The body weight gain
decreased from 1.76 to 0.46 g/day after 4 months of NCC
implant. The fasting glucose decreased from 87.7 to 75.3 mg/
dl at terminal day. The duodenal muscle layer covered by the
NCC increased from 0.133 to 0.334 mm. After 4 weeks of
NCC removal, the food intake, body weight gain, and fasting
glucose recovered to 36.2, 2.51 g/day, and 83.9 mg/dl. The
duodenal muscle layer covered by the NCC decreased to
0.217 mm.
Conclusion The NCC implant placed on the proximal duode-
num is safe in rats for a 4-month period. The efficacy of the
NCC implant is significant for decrease in food intake, body
weight gain, and fasting glucose in a normal rat model. The
removal of NCC implant confirmed a cause-effect relation
with food intake and hence body weight.
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Introduction
Obesity increases the risk of diabetes, stroke, hypertension,
heart disease, kidney disease, liver disease, gallbladder dis-
ease, degenerative diseases, and depression, among other
disorders [1, 2]. Weight loss has been found to improve or
resolve these comorbidities [3–10]. Surgical intervention pro-
vides effective treatment for severe obesity [6–11]. Bariatric
surgery (e.g., Roux-en-Y gastric bypass, RNY; adjustable
gastric banding, AGB; vertical sleeve gastrectomy, VSG;
biliopancreatic diversion; and duodenal-jejunal exclusion)
based on gastrointestinal restriction or malabsorption provides
sustainable, profound weight loss [5–17]. The emerging evi-
dence in bariatric surgery that surgical manipulations of the
gastrointestinal anatomy can bring about weight-independent
improvements in glycemic control have led to interest in the
gastrointestinal tract as a target for the development of new
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treatments for obesity and diabetes [18–28], albeit the mech-
anisms of weight loss with many of these procedures are not
fully understood. Animal studies suggest that exclusion of
chyme from the mucosa and mucosal/submucosal secretions
in the proximal small intestine directly and positively affects
glucose homoeostasis [8, 15–20]. This finding has prompted
the development of devices aiming to mimic the foregut
exclusion of bypass procedures [27, 28].
Here, we developed a reversible intervention to achieve
weight loss. We previously observed acute reduction of duo-
denal motility by peri-duodenal non-constrictive cuff [29]. In
this study, we implanted an external peri-duodenal non-con-
strictive cuff (NCC) around the proximal duodenum adjacent
to the pyloric sphincter. The NCC did not result in physical
stenosis since the internal diameter of the NCC was greater
than the duodenal major diameter at physiological distension.
The application of the NCC acutely reduces duodenal con-
tractility during elevation of intraluminal pressure [29]. The
safety, efficacy, and reversibility of the implantation of NCC
were evaluated over a 4-month period.
Materials and Methods
Eighteen Wistar rats weighing 495±27 g (472–523 g) were
obtained from Charles River. The animals had ad libitum
access to water and food and were randomly distributed in
sham group (n=6), cuff implantation group (n=6), and cuff
removal group after the same period of the implantation group
(n=6). A room temperature of 20 to 22 °C and humidity of 30
to 70% were maintained. The animals were carefully checked
for preexisting disease and acclimated for a week before
undergoing the surgical procedure. All animal experiments
were performed in accordance with national and local ethical
guidelines, including the principles of laboratory animal care,
the Guide for the Care and Use of Laboratory Animals and the
National Society for Medical Research, and an approved
Indiana University School of Medicine IACUC protocol re-
garding the use of animals in research.
An NCC was made of implantable silicone rubber, and the
wall of NCC was impermeable. The internal and external
diameters of NCCwere 6 and 7.5 mm, respectively, with axial
length of ~2 mm (Fig. 1). The NCC can be opened into a
sector for implantation with axial slit of 0.7 mm. The axial gap
through the NCC allows the mesentery to pass through the
NCC without injury or damage to preserve the blood vessels
and neural fibers of the intestine (Fig. 1). Ten or 11 NCCs
were implanted in tandem along the small intestine to cover a
desired length of the small intestine (Fig. 1).
Surgical anesthesia was induced with and maintained with
isoflurane 1.3–1.6 %. Ventilation was provided with a respi-
rator (Harvard Instrument, Inc), and a heating pad was used to
maintain body temperature. The adequacy of anesthesia was
confirmed by stability of respiration rate and no limb with-
drawal reflex. The abdominal skin and muscle layers were
incised at a central line. The stomach and proximal duodenum
were exposed to provide access for the implant. In the implan-
tation group, ten or 11 NCC were opened by forceps and
slipped into the space between the duodenum and right hepat-
ic lobe. The NCC were individually mounted along the duo-
denum which covered ~22 mm of duodenum length from the
pyloric sphincter toward the distal duodenum. In the removal
group, all NCC were removed surgically after 4 months, and
the animals were survived for additional 4 weeks. The ab-
dominal muscular layer was sutured using absorbable suture,
and the skin was closed by silk suture. In the sham group, six
pieces of silicone rubber ~4×2×1.5 mm (L×W×H) were
placed on surface of duodenum. The rats were recovered
and had free access to food and water.
The activity and behavior of rats were evaluated daily. The
food intake and body weight were measured weekly. The
incremental food intake or bodyweight per day was calculated
weekly and divided by seven. The fasting glucose in the
implant group was measured at 16 weeks and removal group,
at 20 weeks.
At termination day, the animals were anesthetized with
isoflurane, and a blood sample was collected from the jugular
vein. The abdominal skin and muscle layers were reopened.
The animal was sacrificed with an overdose of pentobabital.
The stomach and small intestine were excised and immediate-
ly stored in 4 °C physiological saline solution (PSS) (in
mmol/l, 142 NaCl; 4.7 KCl; 2.7 Sodium HEPES, three
HEPES acid, 1.17 MgSO4, 2.79 CaCl2, and 5.5 glucose).
The covered duodenum was separated carefully from the
Fig. 1 Schematic of NCC implanted on the proximal duodenum. Left top
panel shows a NCC with dimensional parameters. Right panel shows the
position and region of NCC implant where the NCC was implanted
around the proximal duodenum adjacent to the pyloric sphincter
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NCCs. A ~6-mm segment of the covered duodenumwas fixed
in formalin (10 %) for histological analysis. Similarly, a ~6-
mm segment of uncovered duodenum, proximal and distal
jejunum, and ileum were fixed in formalin for histological
analysis. Finally, a ~8-mm segment of lower stomach was
fixed in formalin for histological analysis.
The fixed samples were embedded in paraffin, and 5-μm
sections were placed on slides. Hematoxylin and eosin stain-
ing was performed for morphometric measurement. For each
segment, 4~5 slides were analyzed. A minimum of ten well-
oriented wall thicknesses of mucosa and muscle layers were
measured.
Statistical Analysis The data were presented as mean±SD,
and significant differences between two groups was deter-
mined by Student’s t test (two-tailed distribution, two-
sample unequal variance). Significant differences between
the dose-response groups were determined by the use of
Bonferroni post hoc test following analysis of variance
(ANOVA) between groups. A probability of p<0.05 was
considered to be indicative of a statistically significant
difference.
Results
After ~4 days post-op, the activity of rats was completely
restored to the level before implantation. No distress was
found in any implanted rats. Water consumption did not
change (40–50 ml/day) after NCC implantation. The behavior
of rats did not change after NCC implantation. There were not
any signs of pain or distress in any rats. At termination study,
no inflammatory response was found in the gastrointestinal
system. A typical gastrointestinal image with the NCC im-
plant was presented in Fig. 2. The NCC implant significantly
changed food intake and body weight of rats as compared to
sham. In the sham group, the daily increase in food intake and
body weight reflected normal growth of rats (Fig. 3). In the
NCC implant group, the daily food intake significantly de-
creased in comparison with the sham group (Fig. 3a). The
body weight gain significantly retarded as compared to nor-
mal growth in the sham group (Fig. 3b). We found that fasting
glucose in plasma was lower in the NCC implant group as
compared to the sham (Fig. 4). A decrease in mucosal layer
and villi height of the gastric wall was observed, and the
thickness of gastric muscle layers did not change significantly
(Fig. 5a). The proximal duodenal muscle layer that was cov-
ered by the NCC significantly thickened both in the circum-
ferential and the longitudinal muscle layers (Fig. 5b).
Furthermore, the thickening of the duodenal segment covered
by the NCC was mainly a result of smooth muscle hypertro-
phy (Fig. 6). The distal duodenal muscle layer that was not
covered by the NCC did not change significantly, albeit it
tended to decrease (Fig. 5b). The mucosa thickness and villi
Fig. 2 A typical in vitro image of the stomach and small intestine with
NCC implant. The stomach and intestine are clear. The implant was
embedded in connective tissue. No significant scarring tissue was found
-5
-4
-3
-2
-1
0
1
2
3
4
5
0 2 4 6 8 10 12 14 16 18 20 22
In
cr
ea
m
en
ta
l B
od
y 
W
ei
gh
t (
g/
da
y)
Post-op Weeks
NCC Implant
Sham
Removal surgery
*
*
*
*
*
* * *
*
* * **
*
*
0
10
20
30
40
50
0 2 4 6 8 10 12 14 16 18 20 22
In
cr
em
en
ta
l F
oo
d 
In
ta
ke
 (g
/d
ay
)
Post-op Weeks
NCC Implant
Sham
Removal surgery*
* *
* * * *
**
* *
*
** *
A
B
Implant surgery
Implant surgery
Fig. 3 Growth observations in the study period. a Body weight gain was
also retarded by the NCC implant. The NCC removal significantly
recovered the gain. b Food intake was significantly reduced by the
NCC implant. The food intake was reversed by NCC removal. #:
p<0.05 ANOVA followed by post hoc Bonferroni. (Asterisk) p<0.05 in
comperison with sham
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height did not change in either proximal (NCC-covered)
or distal (no NCC) duodenum (Fig. 5b). The jejunal
ileal muscle layers did not change in NCC implant
(Fig. 5c, d). The jejunal and ileal mucosa thickness
and villi height significantly decreased in NCC implant
in comparison with sham (Fig. 5c, d).
To examine the cause-and-effect relation, we removed the
NCC after 16 weeks of implant. Although fibrotic tissue
covered the NCC, the duodenal serosa covered by the NCC
did not stick to the internal or external surface of the NCC.
The NCC was easily removed by a ~2-mm incision along the
fibrotic tissue. After 4 weeks from the removal, the daily
incremental food intake and body weight increased to similar
levels of the sham group (Fig. 3). The fasting glucose was no
longer statistically lower than the sham group (Fig. 4). The
morphometric data also tended to recover to sham levels
(Figs. 5 and 6). As expected, the body weight (593 g) in the
removal group was significantly lower than that in the sham
group (669 g) since the weight gain in the removal group was
16 weeks behind the sham group.
Discussion
The safety and efficacy of novel NCC implants on proximal
duodenum were evaluated. The NCC implants did not result
in any notable safety risk for the duration of 16 weeks. The
food intake, body weight, and glucose of the rats were
Fig. 4 Fasting glucose in the implant. The NCC implant significantly
suppressed fasting glucose after 4 months. The fasting glucose was
reversed by NCC removal. (Asterisk) p<0.05 Student’s t test in
comparison with sham
Fig. 5 Morphometric measurements of stomach and small intestine. a
Stomach. Both mucosa and villi height decreased in the stomach and
were reversed by the removal of NCC. b Duodenum. Muscle thickening
is significant. Both circumferential and longitudinal muscle layers were
proportionally thickened. The removal of the implant reversed muscle
thickening. c Jejunum. d Ileum. Bothmucosa and villi height decreased in
the jejunum and ileum and were reversed by the removal of NCC.
(Asterisk) p<0.05 Student’s t test in comparison with sham
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suppressed in the NCC group. The thickness of the duodenal
muscle layer covered by NCC doubled while the mucosal
thickness of the jejunum and ileum decreased significantly.
The removal of NCC reversed food intake, body weight, as
well as the morphometric parameters of the small intestine.
The recovery of the former supports a cause-and-effect rela-
tion for the device while restoration of the latter suggests
reversible non-pathological remodeling.
Body weight is the result of complex physiologic mecha-
nisms that control food intake and energy expenditure in
which neural and hormonal signals are involved [15].
Control of body weight is a significant topic in the design of
effective treatments for obesity. Bariatric surgery provides
decrease in body weight and has become a common treatment
for obesity. It is currently recognized as an effective treatment
for prevention, control, or reversion of the comorbidities
including metabolic disease [18–25]. While multiple surgical
approaches, including RNY, VSG, and laparoscopic AGB,
have shown efficacy in achieving weight loss and
improving/eliminating obesity-related conditions, the bariatric
procedure penetration rate remains quite low at approximately
1 % of the obese population. A significant reason for low
penetration rate is patient reluctance because of the many
shortcomings of the available procedures [30, 31]. The most
notable shortcomings include permanence or irreversibility,
staple line leak complications, and nutritional deficiencies [30,
32, 33], in the case of purely surgical approaches. In the case
of AGB, the complications include frequent adjustment re-
quirements, esophageal distention (including achalasia), and
insufficient weight loss, leading to up to 50 % band
removal as recently reported [32, 33]. The proposed
NCC provides a number of advantages including effica-
cy in the limitation of food intake and body weight,
reversibility, elimination of the staple-related complica-
tions, no esophageal distensions, and no indications of
gastrointestinal rupture.
Pyloric adjustable banding, an AGB implanted at the py-
loric sphincter, has been employed to regulate gastric empty-
ing rate [34]. Food intake reduction and weight loss were
observed after inflation of the pyloric band. The incidence of
gastric dilation, however, was high [34] because the pyloric
adjustable banding creates a significant physical obstruc-
tion which is different from the NCC employed in this
study. The diameter of NCC is 6 mm which is ~20 %
larger than the duodenal diameter (~5 mm), and it was
placed in the proximal duodenum from the pyloric sphinc-
ter toward the middle duodenum. The mechanism NCC
efficacy is unclear and requires further investigation.
Although NCC is not physically obstructive, it may acute-
ly attenuate duodenal contractility in response to pressure
stimulus [29]. The reduction of motility may extend,
however, beyond the covered port ion [35, 36].
Furthermore, the motility reduction at the covered region
likely transmits feedback to the entire GI system [37–42].
It is well-known that a reduction in motility may produce
two major results: (1) increase of the sustained time of
chyme in the stomach or a delay of the gastric emptying
(satiety persistence) and (2) mixing reduction of nutrient
chyme in the duodenum for delivery of premature nutri-
ents to the jejunum (malabsorption).
The NCC-induced duodenal remodeling thickens the mus-
cle layer covered by NCC and did not affect the duodenal
mucosa (Fig. 5a). The regional thickening of the duodenal
muscle covered by NCC is interesting since the muscle layer
of contiguous distal duodenum is not thickened. The effect of
NCC on muscle thickness is limited to the region of NCC
where the contraction is attenuated [29]. The mechanism of
muscle thickening is unclear, and it is likely compensatory to
the reduced contractility since the NCC attenuates duodenal
motility.We also observed significant increase in the duodenal
lumen at NCC implant sites. This may be evidence of duode-
nal motility attenuation since chyme transportation merely
depends on passive pressure difference between the stomach
and distal NCC. We also observed that the NCC implant
decreased jejunal and ileal mucosal thickness (Fig. 5b, c)
which suggests that the effect of NCC extends along the entire
small intestine. This is in agreement with bariatric experience
where the effect is not regional but global. The NCC implant
also significantly affected gastric morphometric parameters
(Fig. 6) likely due to the increased resistance of chyme trans-
portation. Therefore, the NCC implant induces some gastro-
intestinal remodeling likely as adaption of gastric motility
Fig. 6 Histologic slides of the
duodenal segment in the NCC. a
Sham. b The NCC covered. ×20
objective. The muscle layers
covered by the NCC were
approximately equal to those of
sham. The average distend
between the nuclei of smooth
muscle cells increased
significantly
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similar to bariatric surgery but with the advantage of
reversibility.
The removal of the NCC was rather simple with no com-
plications. We found restoration of food intake, body weight
gain, intestinal muscle, and mucosal layers post removal.
Since the NCC implant does not change the gastrointestinal
anatomy, reversibility was expected after NCC removal.
Although we demonstrated that gastrointestinal contraction
is acutely attenuated by NCC, it remains whether NCC im-
plant chronically attenuates gastrointestinal motility, e.g.,
chyme dynamical transportation, bolus transient time, etc.
The understanding of efficacy requires future study of gut
pathway activation, particularly the peptide hormone secre-
tions, non-peptide signals transported across the mucosa, en-
teric neuronal circuits and communication, and autonomic and
central nervous system interactions. The efficacy of NCC
implant should also be validated in animal models of meta-
bolic syndrome, e.g., obesity and type II diabetes.
In summary, the NCC implant on proximal duodenum is
safe in rats for 4 months. The efficacy of the NCC implant was
demonstrated by the decrease in food intake, body weight
gain, and fasting glucose. The gastrointestinal remodeling
and adaptation was substantially restored after NCC removal.
The reversibility of the NCC implant also restored food intake,
body weight gain, and fasting glucose, which confirmed cau-
sation of the implant. Understanding the mechanism of NCC
implant may lead to new strategies and approaches for the
treatment of obesity and diabetes.
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